Novartis has claimed a first-in-class regulatory approval in the US for oral BTK inhibitor remibrutinib as a second-line treatment for chronic spontaneous urticaria (CSU), also known as chronic hives.

What Is Rhapsido, and Why Does It Matter? Rhapsido (remibrutinib) is a new oral medicine approved to treat adults with chronic spontaneous urticaria (CSU). CSU is a long-term skin condition that ...

Since the launch of the Crossword in 1942, The Times has captivated solvers by providing engaging word and logic games. In 2014, we introduced the Mini Crossword — followed by Spelling Bee, Letter ...

That may surprise some readers, but Whitehouse’s point is that a beehive is as natural as a pasture full of grazing sheep and ...